ANVISA GMP certification received for Bhayla manufacturing facility
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts more than Nifty Microcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Corona Remedies has received GMP certification from Brazil's health regulator ANVISA for its Bhayla, Ahmedabad facility, covering OSD (Oral Solid Dosage) and Women's Hormone production lines. This is the company's third major GMP accreditation, following EU-GMP and EAEU-GMP approvals. While India remains its primary market, contributing over 96 percent of revenue, the certification strengthens manufacturing credentials for international expansion. Brazil is a USD 44 billion pharmaceutical market, presenting future growth opportunities. The certification aligns with the company's One World, One Quality philosophy and supports potential export ambitions into Latin America.
Strengthens manufacturing credentials and opens doors to the Latin American market, but India still drives 96 percent of revenue so near-term financial impact remains limited.